ACORDA - Walking Tall - Promise of Further Growth
Acorda (ACOR) has reached sustainable profitability through the sales of its marketed drug AMPYRA (dalfampridine, L, partnered with Biogen for EU, walking improvement in MS pts). We expect further growth in AMPRYA uptake in US (increased pt awareness), geographical expansion by partner Biogen and future label expansion in Cerebral Palsy and Chronic Stroke. Through acquisition and alliances, ACOR’s diversification strategy (Pipeline beyond AMPYRA) should unfold successfully in coming years.. For more detail, please read our report released on 5th March, 2012 on Acorda titled “Walking Tall - Promise of Further Growth”
COMPANIES MENTIONED
Acorda
Acorda
